CRISPR Therapeutics (NASDAQ: CRSP) is gaining in prominence. The gene-editing specialist has made tremendous clinical and regulatory progress since its 2016 initial public offering, leading to market-beating returns even if it hasn't always been smooth sailing. And there may yet be plenty of upside left for the company. Gene editing could help revolutionize how we treat many challenging conditions -- and the frontrunners in the field will likely be well-rewarded.

However, investors might also be worried that the best is in the rearview mirror for CRISPR Therapeutics. Can the mid-cap biotech still deliver outsized returns? Let's find out.

Continue reading

Source Fool.com